^
Association details:
| Biomarker: | MSLN expression |
|---|---|
| Cancer: | Ovarian Cancer |
| Drug: | RG7600 (Microtubule inhibitor, Mesothelin-targeted antibody-drug conjugate) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Phase I Study of DMOT4039A, an Antibody–Drug Conjugate Targeting Mesothelin, in Patients with Unresectable Pancreatic or Platinum-Resistant Ovarian Cancer
Excerpt:
One female ovarian cancer patient with a response to treatment (Fig. 2B) was a 59-year-old woman previously treated with carboplatin/paclitaxel. This patient received DMOT4039A at a dose of 2.4 mg/kg q3w. Archival tissue showed IHC 3+ staining for mesothelin. She achieved significant clinical improvement in the first cycle...
DOI:
https://doi.org/10.1158/1535-7163.MCT-15-0693
